Trillium Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Trillium Therapeutics's estimated annual revenue is currently $1.3M per year.
- Trillium Therapeutics's estimated revenue per employee is $77,500
- Trillium Therapeutics's total funding is $46M.
Employee Data
- Trillium Therapeutics has 17 Employees.
- Trillium Therapeutics grew their employee count by -15% last year.
Trillium Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | EVP and Chief Medical Officer | Reveal Email/Phone |
3 | Associate Director Clinical Operations | Reveal Email/Phone |
4 | Chief Development Officer | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | Chief Scientific Officer | Reveal Email/Phone |
7 | Associate Director, QA and Regulatory Compliance | Reveal Email/Phone |
8 | Clinical Trial Manager | Reveal Email/Phone |
9 | Scientist - Translational Research | Reveal Email/Phone |
10 | Protein Biochemistry Research Associate | Reveal Email/Phone |
Trillium Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Trillium Therapeutics?
Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective ￃﾢ￢ﾂﾬￅﾓdo not eatￃﾢ￢ﾂﾬￂﾝ signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this ￃﾢ￢ﾂﾬￅﾓdo not eatￃﾢ￢ﾂﾬￂﾝ signal with decoy receptors, we aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.
keywords:N/A
$46M
Total Funding
17
Number of Employees
$1.3M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Trillium Therapeutics News
Pfizer has invested in a clutch of publicly traded companies including Homology Medicines and Trillium Therapeutics through the initiative.
Pfizer has invested in a clutch of publicly traded companies including Homology Medicines and Trillium Therapeutics through the initiative.
The big drugmaker closed on its $2.22 billion acquisition of Trillium Therapeutics in November 2021. But an even bigger deal was right...
Trillium Therapeutics Receives Final Court Order Approving Arrangement CAMBRIDGE, MA, October 28, 2021 Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to ...
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from th ...
Other Companies in Mississauga
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.1M | 17 | N/A | N/A |
#2 | $1.5M | 17 | N/A | N/A |
#3 | $1.5M | 17 | N/A | N/A |
#4 | $1.5M | 17 | N/A | N/A |
#5 | $1.5M | 17 | N/A | N/A |